Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Icecure Medical ( (ICCM) ) has issued an announcement.
On January 27, 2025, IceCure Medical announced the filing for regulatory approval of its ProSense® Cryoablation System in China, aiming to expand its market in the region where its IceSense3 system is already approved. This move highlights IceCure’s strategic focus on leveraging China’s potentially large market for cryoablation technology, enhancing its product offerings and securing reimbursement to strengthen its industry position and stakeholder value.
More about Icecure Medical
IceCure Medical, based in Caesarea, Israel, develops and markets advanced cryoablation technology for tumor destruction using liquid nitrogen. Their minimally invasive solutions focus on treating breast, kidney, bone, and lung cancers, offering a safe alternative to surgical tumor removal. The company’s flagship ProSense® system is globally marketed, with approvals in regions including the U.S., Europe, and China.
YTD Price Performance: 0.81%
Average Trading Volume: 733,068
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $70.15M
Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.
